Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, Mantle-Cell: early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Lymphoma, Mantle-Cell: 8 US clinical trials tracked, none currently recruiting.
Lymphoma, Mantle-Cell is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition lymphoma-mantle-cell
OPEN 0 | RECR 0% | LATE 2 | EARLY 5 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Lymphoma, Mantle-Cell has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, Mantle-Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, Mantle-Cell is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lymphoma, Mantle-Cell research.
National Cancer Institute (NCI) accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma, Mantle-Cell trials plan to enrol fewer than 100 people.
Median target enrolment is 64 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Lymphoma, Mantle-Cell research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma
NCT02972840
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Loxo Oncology
NCT04662255
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
NCT05024045
A Safety Study of SGN-CD19A for B-Cell Lymphoma
Seagen
NCT01786135
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Cancer Institute (NCI)
NCT00114738
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Triphase Research and Development III
NCT03682796
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
Celgene
NCT02341781
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Cancer Institute (NCI)
NCT00005780
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, Mantle-Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, Mantle-Cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, Mantle-Cell page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Lymphoma, Mantle-Cell trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Lymphoma, Mantle-Cell trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, Mantle-Cell condition card totals 8 registered trials; most-linked intervention Acalabrutinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.